Advancing EU Health Technology Assessment: Insights from the HAG Meeting

By João L. Carapinha

January 20, 2025

In this article we report on a virtual meeting of the Heads of HTA Agencies Group (HAG) held on January 14, 2025, two days after the implementation of the EU Health Technology Assessment (HTA) Regulation. The meeting discussed key developments, including the drafting of implementing acts for joint scientific consultations and clinical assessments. Also, they focused on the operationalization of the 2025 Work Programme for the new joint EU-level HTA framework. The HAG also addressed various initiatives, such as the HAG INSIGHT initiative and the launch of the HAG Digital Medical Device Working Group.

Key Insights

The HAG meeting concentrated on the implementation of the EU Health Technology Assessment Regulation, particularly the drafting and approval of procedural rules for joint scientific consultations (JSC) and joint clinical assessments (JCA) of medical devices and IVD medical devices.

The group discussed ongoing initiatives, including the HAG INSIGHT initiative aimed at enhancing the capacity and expertise of EU HTA bodies. They also discussed the launch of the HAG Digital Medical Device Working Group.
– Positive feedback from stakeholder events organized in 2023 and 2024 was highlighted, alongside discussions about the development of the HAG Strategic Plan 2025-2028.
– Data transparency in EU joint clinical assessments and the evaluation of the EU Health Technology Assessment Regulation under Article 31 were also key topics.

Context

The EU Health Technology Assessment Regulation (EU) 2021/2282 came into effect on January 12, 2025. Its goal is to reduce duplication for national HTA authorities and the industry while improving the evidence base for HTA assessments. The regulation encompasses joint clinical assessments and scientific consultations, which are essential for harmonizing HTA processes across EU member states. The preparatory phase of this regulation lasted from January 2022 to January 2025, involving the development of implementing legislation, guidance documents, and stakeholder engagement.

Implications

The implementation of the EU Health Technology Assessment Regulation is expected to streamline and standardize the HTA process, potentially leading to more efficient and cost-effective assessments of health technologies. This reform may significantly impact patient access by lessening the financial burden linked to duplicate assessments and by enhancing the quality of evidence for decision-making. Enhanced data transparency in joint clinical assessments, as discussed by the HAG, will likely boost the reliability and comparability of HTA outcomes, benefiting both healthcare providers and patients. The HAG INSIGHT initiative and other capacity-building efforts will ensure that EU HTA bodies possess the expertise necessary to implement the HTA Regulation effectively while maintaining high standards in health technology evaluations.

The regulation emphasizes voluntary cooperation among member states and stakeholder engagement, which includes patient and clinician organizations, industry representatives, and national authorities. This collaboration can drive better health outcomes and more informed policy decisions. The inclusion of new members in the HAG and the expansion of its working groups, such as the HAG Digital Medical Device Working Group, will further increase the group’s representativeness and efficacy in supporting the implementation of the HTA Regulation across the EU.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.